(Q34646570)

English

Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older

scientific article

Statements

Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older (English)
0 references
0 references
0 references
0 references
17 December 2012

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit